How to Navigate the FDA Landscape for an Orphan Drug
Rare diseases are a public health priority. FDA has launched several programs and a final…
CertaraFebruary 21, 2024
Dose Optimization Considerations for Targeted Radiation Therapies
The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio…
CertaraFebruary 16, 2024
The interaction of core modules as a basis for elucidating network behavior determining Parkinson’s disease pathogenesis
It is well-established that misfolded alpha-synuclein (alpha-syn) is a histopathological marker of Parkinson's disease. Given…
CertaraFebruary 14, 2024
Advancing Services & Software for INDs: How to Expedite IND Filing with a Subscription Model
When choosing how to accomplish your IND submission, there can be many elements to the…
CertaraFebruary 13, 2024
D360 Scientific Informatics Discovery Platform: User Stories
Transcript: I've joined companies both blueprint medicines and score therapeutics is one of the first…
CertaraFebruary 8, 2024
Upping the Ante for Predicting the Success of Alzheimer Disease Treatments
By Hugo Geerts, PhD, Piet van der Graaf, PharmD, PhD Over the past 20 years,…
CertaraFebruary 8, 2024
